Related Experiment Videos
F VIII subunits: purification and antigenic properties
O Nordfang1, M Ezban, J J Hansen
1Nordisk Gentofte A/S, Denmark.
Thrombosis and Haemostasis
|December 18, 1987
Summary
Factor VIII-Light Chain (FVIII-LC) can block inhibitor antibodies in hemophilia A patients, suggesting its use in immunotherapy. Purified FVIII-LC shows potential for removing these antibodies via extracorporeal treatment.
Area of Science:
- Immunology
- Hematology
- Biochemistry
Background:
- Hemophilia A is characterized by inhibitors against Factor VIII (FVIII).
- Identifying specific FVIII subunits targeted by inhibitors is crucial for treatment.
- Current treatments for inhibitor patients are limited.
Purpose of the Study:
- To purify and characterize Factor VIII-Light Chain (FVIII-LC) and Factor VIII-Heavy Chain (FVIII-HC).
- To assess the inhibitory potential of purified FVIII-LC and FVIII-HC against FVIII inhibitor antibodies.
- To explore the therapeutic application of FVIII-LC in hemophilia A immunotherapy.
Main Methods:
- Purification of FVIII-LC and FVIII-HC using immunosorbents and cation exchange chromatography.
- FVIII:C inhibition assays with hemophilia A inhibitor plasmas.
- Coupling of FVIII-LC to Sepharose for ex vivo antibody removal.
Main Results:
- FVIII-LC preparations were obtained with high purity.
- FVIII-LC effectively blocked inhibitor activity in 6 out of 7 hemophilia A plasmas.
- FVIII-HC showed limited blocking activity.
- FVIII-LC-Sepharose efficiently bound FVIII inhibitor antibodies from plasma.
Conclusions:
- FVIII-LC is a potential target for immunotherapy in hemophilia A patients with specific inhibitors.
- Extracorporeal removal of FVIII inhibitor antibodies using FVIII-LC-Sepharose is a viable therapeutic strategy.